Charles River Laboratoriesvs.IQVIA Holdings
CRL vs IQV · both in CDMO & pharma manufacturing, part of the Medicine, pharma & life science value chain: Contract development and manufacturing of medicines, the industrial backbone behind the drugs.
IQVIA Holdings is about 2.9× larger than Charles River Laboratories by market cap; year to date, Charles River Laboratories leads (+49.7% vs +15.5%).
Side by side
| CRL | IQV | |
|---|---|---|
| Market cap | $13.6B | $39.4B |
| Price | $297.64 | $259.42 |
| Today | −0.3% | −0.3% |
| Return YTD | +49.7% | +15.5% |
| Return 1Y | +84.5% | +36.1% |
| P/E | — | 28.6 |
| P/S | 3.4 | 2.3 |
| P/B | 4.8 | 6.4 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
Charles River LaboratoriesCRL
Preclinical work that drug and biotech companies choose not to do in-house: research models, safety testing, laboratory services through development, and support for cell and gene therapy.
Full CRL profile →IQVIA HoldingsIQV
Drug companies outsource clinical trials to IQVIA, and many of the same customers buy its health data and analytics. A third arm sells commercial services to the pharmaceutical industry.
Full IQV profile →More CRL & IQV comparisons
Other head-to-heads in the CDMO & pharma manufacturing segment.